TG Therapeutics Inc (NASDAQ:TGTX) – Equities research analysts at Jefferies Financial Group dropped their Q2 2019 earnings per share estimates for TG Therapeutics in a research report issued on Monday, May 13th. Jefferies Financial Group analyst C. Howerton now anticipates that the biopharmaceutical company will post earnings of ($0.48) per share for the quarter, down from their prior forecast of ($0.47). Jefferies Financial Group currently has a “Buy” rating and a $8.00 price target on the stock. Jefferies Financial Group also issued estimates for TG Therapeutics’ Q3 2019 earnings at ($0.46) EPS, Q4 2019 earnings at ($0.44) EPS, FY2019 earnings at ($1.81) EPS, FY2020 earnings at ($1.29) EPS and FY2021 earnings at ($1.06) EPS.
TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.01. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 99,471.43% and a negative return on equity of 309.17%.
Shares of NASDAQ TGTX opened at $7.10 on Wednesday. The company has a current ratio of 1.72, a quick ratio of 2.03 and a debt-to-equity ratio of 1.89. TG Therapeutics has a 12-month low of $3.32 and a 12-month high of $16.00.
Institutional investors have recently added to or reduced their stakes in the business. Ladenburg Thalmann Financial Services Inc. lifted its position in TG Therapeutics by 46.5% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,927 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 2,200 shares during the period. Advisor Group Inc. raised its position in shares of TG Therapeutics by 23.6% in the 1st quarter. Advisor Group Inc. now owns 7,850 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 1,500 shares during the period. Forbes J M & Co. LLP acquired a new stake in shares of TG Therapeutics in the 4th quarter valued at approximately $44,000. LPL Financial LLC acquired a new stake in shares of TG Therapeutics in the 4th quarter valued at approximately $49,000. Finally, NumerixS Investment Technologies Inc acquired a new stake in shares of TG Therapeutics in the 4th quarter valued at approximately $50,000. Institutional investors own 55.26% of the company’s stock.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Featured Story: Bollinger Bands
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.